Monoclonal antibodies to myeloid differentiation antigens: in vivo studies of three patients with acute myelogenous leukemia

摘要: Three patients with acute myelogenous leukemia (AML) in relapse were treated intravenous infusions of one or more purified murine monoclonal antibodies (MoAbs) specific for differentiation antigens on normal and malignant myeloid cells. the MoAbs used IgM immunoglobulins that react glycolipids, while fourth, an IgG2b, reacts a protein antigen. Peripheral blood cell counts decreased significantly, but transiently, during treatment. Evidence vivo binding each MoAb to cells was obtained, although two four could not be detected plasma following infusion, perhaps due circulating blocking factors. Antigenic modulation encountered these studies. However, induction human antibody observed patient who over 70-day period. Toxicities minimal included fever (3 patients), back pain (1 patient), arthralgias myalgias patient). This is first reported clinical trial (1) MoAbs, (2) therapy AML, (3) combinations directed toward different antigens, (4) glycolipids. The relative lack toxicity positive effects treatment reduction permit continued study innovative approaches AML MoAbs.